Literature DB >> 30328737

Rationale and patient selection for interventional therapies in Parkinson's disease.

Junaid Siddiqui1, Zakiyah Aldaajani2, Raja Mehanna3, Barbara Kelly Changizi4, Danish Bhatti5, Ziyad Ghazi Al-Johani6, Aparna Wagle Shukla7, Hubert H Fernandez8, Jawad A Bajwa9.   

Abstract

INTRODUCTION: Parkinson's disease (PD) is increasing in prevalence due to a growing elderly population. Although there is no cure, there are exercise therapies and medications for mild to moderate disease. For more advanced disease, infusion or surgical interventions including deep brain stimulation surgery, levodopa carbidopa intestinal gel, and subcutaneous apomorphine infusion are considered. As these interventions become increasingly available, it is imperative for a neurologist involved in the care of advanced PD to be aware of the indications and timing for these interventions. Areas covered: This article attempts to identify different patient profiles and matches them with suggested advanced therapies for PD. There is limited literature providing guidance to a busy neurologist to match the most appropriate advanced therapy to the right patient profile. This article attempts to fill that void. Expert commentary: When matching patient profiles to therapy, several features must be considered: age, frailty, cognitive status, phenotype (predominant tremor vs. akinetic rigid), side effect or complication profile (dyskinesia, hallucinations, dysautonomia), and patient's comfort with invasive therapy options.

Entities:  

Keywords:  Parkinson’s disease; advanced therapies; deep brain stimulation; levodopa carbidopa intestinal gel; subcutaneous apomorphine infusion

Year:  2018        PMID: 30328737     DOI: 10.1080/14737175.2018.1535902

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  4 in total

1.  Neurologists' Attitudes Toward Use and Timing of Deep Brain Stimulation.

Authors:  Laura Yenisa Cabrera; Catherine Young Han; Tasha Ostendorf; Joohi Jimenez-Shahed; Harini Sarva
Journal:  Neurol Clin Pract       Date:  2021-12

Review 2.  A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.

Authors:  Philippe A Salles; James Liao; Umar Shuaib; Ignacio F Mata; Hubert H Fernandez
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues.

Authors:  Kristina Hug
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

4.  Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East.

Authors:  Hanan Khalil; Lana M Chahine; Junaid Siddiqui; Mehri Salari; Shaimaa El-Jaafary; Zakiyah Aldaajani; Mishal Abu Al-Melh; Tareq Mohammad Mohammad; Muneer Abu Snineh; Nadir A Syed; Mohit Bhatt; Mohammad Ahsan Habib; Majed Habahbeh; Samer D Tabbal; Beomseok Jeon; Jawad A Bajwa
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.